PE20230181A1 - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents
Uso de reboxetina para tratar los trastornos del sistema nerviosoInfo
- Publication number
- PE20230181A1 PE20230181A1 PE2022000980A PE2022000980A PE20230181A1 PE 20230181 A1 PE20230181 A1 PE 20230181A1 PE 2022000980 A PE2022000980 A PE 2022000980A PE 2022000980 A PE2022000980 A PE 2022000980A PE 20230181 A1 PE20230181 A1 PE 20230181A1
- Authority
- PE
- Peru
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- esreboxetine
- Prior art date
Links
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 4
- 229960003770 reboxetine Drugs 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title 1
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 abstract 3
- 229950008247 esreboxetine Drugs 0.000 abstract 3
- 201000003631 narcolepsy Diseases 0.000 abstract 3
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen los metodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administracion de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) tambien se puede utilizar en la elaboracion de un medicamento para el tratamiento de la narcolepsia con cataplexia. Tambien se dan a conocer en este documento los kits que comprenden una composicion farmaceutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composicion farmaceutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943077P | 2019-12-03 | 2019-12-03 | |
| US201962946295P | 2019-12-10 | 2019-12-10 | |
| US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
| US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230181A1 true PE20230181A1 (es) | 2023-02-01 |
Family
ID=81851750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000980A PE20230181A1 (es) | 2019-12-03 | 2020-11-30 | Uso de reboxetina para tratar los trastornos del sistema nervioso |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4069244A4 (es) |
| JP (1) | JP2023504685A (es) |
| KR (1) | KR20220108122A (es) |
| CN (1) | CN114746097A (es) |
| AU (2) | AU2020395082A1 (es) |
| BR (1) | BR112022010677A2 (es) |
| CA (1) | CA3163505A1 (es) |
| CO (1) | CO2022007507A2 (es) |
| CR (1) | CR20220247A (es) |
| IL (1) | IL293536A (es) |
| MX (1) | MX2022006630A (es) |
| PE (1) | PE20230181A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197983B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
| ATE319453T1 (de) * | 1999-07-01 | 2006-03-15 | Pharmacia & Upjohn Co Llc | Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen |
| EP2167066B1 (en) * | 2007-05-07 | 2013-06-26 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders |
| KR102192554B1 (ko) * | 2013-03-13 | 2020-12-18 | 에스케이바이오팜 주식회사 | 탈력발작의 치료 |
-
2020
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/es unknown
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/pt unknown
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/zh active Pending
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en not_active Abandoned
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/ja active Pending
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/ko not_active Ceased
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/es unknown
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CR CR20220247A patent/CR20220247A/es unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/es unknown
-
2024
- 2024-05-31 AU AU2024203676A patent/AU2024203676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114746097A (zh) | 2022-07-12 |
| CO2022007507A2 (es) | 2022-06-21 |
| MX2022006630A (es) | 2022-06-24 |
| EP4069244A4 (en) | 2023-12-20 |
| EP4069244A1 (en) | 2022-10-12 |
| CA3163505A1 (en) | 2021-06-10 |
| KR20220108122A (ko) | 2022-08-02 |
| CR20220247A (es) | 2022-08-18 |
| BR112022010677A2 (pt) | 2022-08-16 |
| AU2020395082A1 (en) | 2022-06-09 |
| AU2024203676A1 (en) | 2024-06-20 |
| JP2023504685A (ja) | 2023-02-06 |
| IL293536A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| MX2020013104A (es) | Agentes activos y metodos de uso para el tratamiento de trastornos metabolicos y enfermedad hepatica no alcoholica. | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
| CL2019000247A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
| MX2021008941A (es) | Moduladores gpr35. |